Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612626 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL10162407 | 0.94 | CCR2 (0.88) | CCR2KCNH2 | |
| SCHEMBL614776 | 0.94 | CCR2 (0.88) | CCR2KCNH2 | |
| SCHEMBL614556 | 0.94 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL10162357 | 0.94 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL614824 | 0.93 | CCR2 (0.88) | CCR2KCNH2 | |
| SCHEMBL10162096 | 0.93 | CCR2 (0.88) | CCR2KCNH2 | |
| SCHEMBL10162364 | 0.93 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL615762 | 0.93 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL615979 | 0.92 | CCR2 (0.85) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419419-B1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-03 | — | — | EP | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-16 | — | — | US | disclosed |
| WO-2010121046-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CCR2 1/4885KCNH2 1802/4885 |
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CCR2 1/4885KCNH2 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.